Unknown

Dataset Information

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.


ABSTRACT:

Background

Irritable bowel syndrome (IBS) is highly prevalent and presents a clinical challenge. Gelsectan is a medical device containing xyloglucan (XG), pea protein and tannins (PPT) from grape seed extract, and xylo-oligosaccharides (XOS), which act together to protect and reinforce the intestinal barrier.

Objective

The objective of this study is to evaluate the efficacy and safety of XG + PPT + XOS in patients with diarrhoea-predominant IBS (IBS-D).

Methods

In this double-blind study, 60 patients were randomly assigned to receive XG + PPT + XOS or placebo for 28 days, then crossed over to the alternative treatment. Patients were followed for 60 days.

Results

At Day 28, a significantly higher proportion of patients starting treatment with XG + PPT + XOS than

SUBMITTER: Trifan A 

PROVIDER: S-EPMC6794699 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature